Patent · US Active

Compound having KDM5 inhibitory activity and pharmaceutical use thereof

US11691968B2 · kind B2 · utility

1Cited by

1References

3Claims

0Family size

Assignee

ONO PHARMACEUTICAL CO., LTD. · JP

Inventors

Akito Kakuuchi · Osaka, JP
Shuhei UMEMURA · Osaka, JP
Masaki Asada · Osaka, JP
Anatoly RUVINSKY · Lexington, US
Yan Zhang · Fort Washington, US
Hidenori Takahashi · Lagrangeville, US
Goran KRILOV · New York, US
Daigo Inoyama · Ridgewood, US
Kyle D. Konze · New York, US
Mats A. Svensson · New York, US

Key dates

Filing date	Oct 24, 2022
Grant date	Jul 4, 2023
Priority date	—
Expiry date	Oct 24, 2042

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P35/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Disclosed are compounds of following formula (I): in which all symbols have the same meanings as the definitions described in the specification; or a salt thereof. The compounds or a salt thereof are useful as a prophylactic and/or therapeutic agent for cancer, Huntington's disease, Alzheimer's disease and the like.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.